Amount Raised
$50 Million
Round Type
Series A
PortlandHealthcareHealth CareDescription
Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing. OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP). This financing will allow the company to accelerate the development of its proprietary oral HSD-1 inhibitor, SPI-62, which targets the source of steroids that cause toxicity in key tissues
Who to call at Sparrow Pharmaceuticals, and when
A new round usually means Sparrow Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sparrow Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sparrow Pharmaceuticals, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sparrow Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSparrow Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.